阿莫西林结晶尿与阿莫西林诱导的结晶性肾病:叙述性综述
本文综述了阿莫西林结晶尿(AC)和阿莫西林诱导的结晶性肾病(AICN)的定义、流行病学、诊断和管理。AC在接受高剂量静脉阿莫西林(≥150 mg/kg/天)的患者中比既往报道更常见,患病率为24%-41%;AICN患病率尚不明确。AC通常无症状,但突发肉眼血尿伴尿液混浊提示诊断。AICN管理包括停用/减少阿莫西林剂量和容量复苏,10%-40%患者需肾脏替代治疗,无直接归因于AICN的死亡。
要点
- 高剂量静脉阿莫西林(≥150 mg/kg/天)患者中AC患病率为24%-41%,AICN患病率尚不明确。
- AC通常无症状,突发肉眼血尿伴尿液混浊提示诊断,尿中检出阿莫西林三水合物结晶可确诊。
- AICN疑诊依据:高剂量静脉阿莫西林治疗者出现AKI和AC,并排除其他AKI原因。
核心结论
- AC在高剂量静脉阿莫西林患者中较既往报道更常见,AC是AKI的危险因素,AICN可导致AKI但无直接归因死亡。
研究设计与样本
- 叙述性综述,检索范围未明确报告。
主要发现
- AC患病率为24%-41%,AICN患病率尚不明确。
- AC通常无症状,突发肉眼血尿伴尿液混浊提示诊断。
- AICN患者停用阿莫西林后肾功能通常快速恢复,但10%-40%需肾脏替代治疗。
- 无直接归因于AICN的死亡。
关键数值与推荐
- AC诊断依据尿中检出阿莫西林三水合物结晶。
- AICN疑诊标准:高剂量静脉阿莫西林治疗者出现AKI和AC,并排除其他AKI原因(主要为脓毒症和急性间质性肾炎)。
- 无法检测AC时,存在已证实(高血阿莫西林水平和低尿pH)或疑似(快速静脉阿莫西林给药和低血容量)AC危险因素提示诊断。
临床怎么用
- 高剂量静脉阿莫西林治疗患者应监测AKI和AC,突发肉眼血尿伴尿液混浊需警惕。
- 疑诊AICN时停用或减少阿莫西林剂量并容量复苏,以改善肾小管流速和尿量,降低阿莫西林过饱和度。
- 10%-40%的AICN患者需肾脏替代治疗。
局限性
- AC和AICN的确切患病率尚不明确,需未来研究评估。
- 缺乏无创诊断工具,AICN诊断具有挑战性。
- 最佳治疗选择尚未定义,需未来研究确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Amoxicillin crystalluria (AC) refers to the precipitation of amoxicillin in the urine as amoxicillin trihydrate crystals. Amoxicillin-induced crystal nephropathy (AICN) refers to the obstruction of kidney tubules by amoxicillin trihydrate crystals, resulting in acute kidney injury. Usually considered rare and not serious, AC and AICN would be more frequent in patients receiving high-dose i.v. amoxicillin (≥150 mg/kg per day) than previously reported. AC prevalence ranges from 24% to 41%. AICN prevalence remains unclear. AC is generally asymptomatic, but sudden macroscopic hematuria with cloudy urine suggests the diagnosis. AC is diagnosed by detecting amoxicillin trihydrate crystals in urine. AC is a risk factor for acute kidney injury. Diagnosing AICN is more challenging in the absence of noninvasive diagnostic tools. It is suspected in high-dose i.v. amoxicillin-treated patients who develop acute kidney injury and AC, and after excluding other causes of acute kidney injury (mainly sepsis and acute interstitial nephritis). When testing for AC is unavailable, the presence of demonstrated (high blood amoxicillin levels and low urinary pH) or suspected (rapid i.v. amoxicillin administration and hypovolemia) risk factors for AC suggests its diagnosis. AICN management includes discontinuation/reduction of amoxicillin doses and volume resuscitation to improve tubular flow and urine output and decrease amoxicillin supersaturation. Patients generally recover normal kidney function rapidly after stopping amoxicillin, but renal replacement therapy is required in 10%-40% of patients. No deaths have been directly attributed to AICN. Future studies are needed to assess the exact prevalence of AC/AICN and to define optimal therapeutic options.
引用
- Vodovar D, Mousseaux C, Daudon M, et al. Amoxicillin crystalluria and amoxicillin-induced crystal nephropathy: a narrative review. Kidney Int. 2024. PMID: 39490983. doi:10.1016/j.kint.2024.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。